TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 10795956
Drug: Standard Treatment
Normalized name: Azo-Standard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard Treatment (ST, n = 61)
Study: 8447204
Drug: Low-dose adenosine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose adenosine (30 micrograms.kg‐1.min‐1 for 4 hours)
Study: 8447204
Drug: Low-dose adenosine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose adenosine
Study: 3082450
Drug: Completion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Completion of treatment programme and attendance at all follow up visits
Study: 29282948
Drug: Ultrasound guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ultrasound guided injection group
Study: 29282948
Drug: Palpation guided
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Palpation guided injection group
Study: 21095483
Drug: lersivirine 500
Normalized name: Lersivirine
DrugBank: Lersivirine (DB11649)
Approvals — FDA: no, EMA: no, PMDA: no
Description: lersivirine 500 mg BID
Study: 21095483
Drug: lersivirine 750
Normalized name: Lersivirine
DrugBank: Lersivirine (DB11649)
Approvals — FDA: no, EMA: no, PMDA: no
Description: lersivirine 750 mg once daily
Study: 1990191
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg of acyclovir orally two times per day (suppressive therapy)
Study: 1990191
Drug: 200 mg
Normalized name: RNA 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg of acyclovir five times per day for 5 days (for recurrences)
Study: 1990191
Drug: Daily acyclovir
Normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Daily acyclovir therapy (suppressive therapy)
Study: 1990191
Drug: Acute therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acute therapy followed by suppressive therapy
Study: 30571697
Drug: Talking Prescriptions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talking Prescriptions (Talking Rx) intervention including Daily Interactive Voice Response (IVR) call services, Daily tailored medication reminders, and Weekly lifestyle modification messages for 3 months.
Study: 30571697
Drug: Talking Prescriptions
Approvals — FDA: no, EMA: no, PMDA: no
Description: Talking Prescriptions (Talking Rx) intervention for CVA patients.
Study: 22490713
Drug: High-dose tirofiban
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose tirofiban (25 µg/kg bolus followed by 0.15 µg×kg(‐1)×min(‐1) infusion for 36 hours, n = 40)
Study: 22490713
Drug: Standard-dose tirofiban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose tirofiban (10 µg/kg bolus followed by 0.15 µg×kg(‐1)×min(‐1) infusion for 36 hours, n = 40)
Study: 20169258
Drug: Intra-articular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular administration of 10 mg of morphine
Study: 20169258
Drug: Intra-articular administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-articular administration of 20 mL of NS
Study: 10460042
Drug: Testosterone transscrotal
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone transscrotal patch (6 mg/day)
Study: 8546997
Drug: Twice-weekly MPD-PUVA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice-weekly MPD-PUVA
Study: 8546997
Drug: Three times-weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three times-weekly skin typing-PUVA
Study: 318984
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg LOX
Study: 318984
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg LOX
Study: 31339826
Drug: Rituximab maintenance
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab maintenance (375 mg/m2, once every 8 weeks for 2 years)
Study: 31339826
Drug: Observation (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Observation (no additional treatment)
Study: 26521572
Drug: Head-point needle-retaining
Normalized name: Head & Shoulders
Approvals — FDA: no, EMA: no, PMDA: no
Description: Head-point needle-retaining therapy + training (group A)
Study: 19220493
Drug: Ritonavir-boosted protease
Normalized name: Ritonavir
DrugBank: Ritonavir (DB00503)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ritonavir-boosted protease inhibitors
Study: 19220493
Drug: Nonnucleoside reverse
Normalized name: OraVerse
DrugBank: Phentolamine (DB00692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nonnucleoside reverse transcriptase inhibitors (NNRTIs), particularly efavirenz
Study: 11338761
Drug: Aloe vera
Normalized name: ALOE VERA
DrugBank: Aloe vera leaf (DB13906)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aloe vera gel/mild soap
Study: 10210991
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (rhGH) treatment in prepubertal children
Study: 10210991
Drug: Recombinant human
Normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Recombinant human growth hormone (rhGH) treatment in pubertal children
Study: 3356152
Drug: Antiepileptic drug
Normalized name: ANTIEPILEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiepileptic drug study with centralized case validation system
Study: 23877864
Drug: Remifentanil 4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil 4 µg/kg intravenously
Study: 20375299
Drug: GIN therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIN therapy (insulin at 2 mU . kg(‐1) . min(‐1) during surgery, decreased to 1 mU . kg(‐1) . min(‐1) for 24 hours, dextrose 20% infusion)
Study: 20375299
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy (conventional insulin sliding scale)
Study: 21757376
Drug: GIN therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: GIN therapy
Study: 31786872
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy combined with interval cytoreductive surgery
Study: 29188298
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus RT (2 cycles of gemcitabine 1000 mg/m2 on days 1, 8, and 15, and cisplatin 70 mg/m2 on day 2, followed by RT to 4500 cGy in 150 cGy twice-daily fractions over 3 weeks)
Study: 29188298
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (4 cycles of gemcitabine and cisplatin)
Study: 29188298
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus RT
Study: 27075990
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group received a similarly timed sham treatment.
Study: 22093057
Drug: Testosterone undecanoate
Normalized name: Testosterone Undecanoate
DrugBank: Testosterone undecanoate (DB13946)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone undecanoate 1000 mg
Study: 19799810
Drug: Induction-concurrent chemoradiotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction-concurrent chemoradiotherapy (IC/CCRT)
Study: 19799810
Drug: Induction chemotherapy
Normalized name: human sputum, Bordetella pertussis infected
Approvals — FDA: no, EMA: no, PMDA: no
Description: Induction chemotherapy and radiotherapy (IC/RT)
Study: 15716206
Drug: Intravesical hyaluronic
Normalized name: hyaluronate
DrugBank: Hyaluronic acid (DB08818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravesical hyaluronic acid therapy (40 mg weekly for 10 weeks)
Study: 15716206
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (C(max) <350 cc)
Study: 15716206
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (C(max) >/=350 cc)
Study: 8719069
Drug: VIP chemotherapy
Normalized name: VIP
DrugBank: Vasoactive intestinal peptide (DB18634)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VIP chemotherapy (vindesine 3 mg/m2 days 1 and 8, ifosfamide 1200 mg/m2, cisplatin 30 mg/m2 days 1, 2 and 3, repeated every 4 weeks, up to six cycles)
Study: 7004808
Drug: Lactose (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactose (50 g twice a day)
Study: 7004808
Drug: Neomycin (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neomycin (3 g/day) plus milk of magnesia
Study: 31610249
Drug: Whole pelvis
Normalized name: Sus scrofa renal pelvis preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Whole pelvis radiotherapy (WPRT) 46Gy in 23 fractions + 15Gy single dose HDR BT
Study: 31610249
Drug: Prostate-only radiotherapy
Normalized name: Sus scrofa prostate preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prostate-only radiotherapy (PORT) 37.5Gy in 15 fractions + 15Gy single dose HDR BT
Study: 23801770
Drug: 0.5 mg
Normalized name: biotin 0.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg neostigmine
Study: 23801770
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg intravenous butylscopolamine
Study: 17513410
Drug: P125 (1.00
Approvals — FDA: no, EMA: no, PMDA: no
Description: P125 (1.00 g protein . kg BW(‐1). d(‐1))
Study: 17513410
Drug: P94 (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: P94 (0.75 g protein . kg BW(‐1). d(‐1))
Study: 17513410
Drug: P63 (0.50
Approvals — FDA: no, EMA: no, PMDA: no
Description: P63 (0.50 g protein . kg BW(‐1). d(‐1))
Study: 11989524
Drug: Herceptin® (adjuvant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Herceptin® (adjuvant therapy)
Study: 2757898
Drug: Aspirin (SA)
Normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aspirin (SA)
Study: 27993911
Drug: Low-dose oxytocin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oxytocin infusion (10 U in 500 mL normal saline at 36 mL/hour for 4 hours)
Study: 27993911
Drug: Low-dose oxytocin
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose oxytocin infusion plus an additional 2 U of oxytocin given over 10 min immediately after birth
Study: 25951636
Drug: Comprehensive Western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive Western medical treatment plus Compound Yindan Decoction (CYD)
Study: 25951636
Drug: Comprehensive Western
Normalized name: western larch pollen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comprehensive Western medical treatment alone
Study: 20210231
Drug: Thalidomide (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Thalidomide (150 mg orally twice daily on days 2 through 5)
Study: 17349809
Drug: DTaP-IPV plus
Normalized name: DTaP-IPV
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTaP-IPV plus PRP approximately T at separate injection sites (group B)
Study: 12765853
Drug: NNC‐687 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNC‐687 (5 mg)
Study: 12765853
Drug: NNC‐687 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNC‐687 (10 mg)
Study: 12765853
Drug: NNC‐687 (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: NNC‐687 (15 mg)
Study: 8453848
Drug: Erythromycin 500
Normalized name: erythromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 500 mg three times a day for 1 week
Study: 8453848
Drug: Midazolam (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.05 mg/kg) intravenously
Study: 30209073
Drug: Fascia Iliaca
Normalized name: OCTINOXATE .012 mL in 6 mL / OCTISALATE .12 mL in 6 mL TOPICAL CREAM [RIMMEL LONDON MOISTURE RENEW LIPGLOSS - FUSCIA THERAPHY (345)]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fascia Iliaca Compartment Block administered by paramedics as early prehospital pain relief.
Study: 26739688
Drug: Peginterferon lambda
Normalized name: Peginterferon lambda-1a
DrugBank: Peginterferon lambda-1a (DB14767)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peginterferon lambda (180 μg weekly for 48 weeks)
Study: 26739688
Drug: Peginterferon alfa-2a
Normalized name: Peginterferon Alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon alfa-2a (weekly for 48 weeks)
Study: 9875193
Drug: Oral zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral zinc sulfate
Study: 7913205
Drug: Pulsatile insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pulsatile insulin infusion (2.4 mU/kg/min for 2 minutes followed by 10 minutes off)
Study: 7913205
Drug: Continuous insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Continuous insulin infusion (0.4 mU/kg/min)
Study: 7913205
Drug: Pulsatile insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pulsatile insulin infusion
Study: 30399036
Drug: Post-TB treatment
Normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Post-TB treatment MLR
Study: 25659828
Drug: Adjunctive zonisamide
Normalized name: Zonisamide
DrugBank: Zonisamide (DB00909)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Adjunctive zonisamide (target dose 8 mg/kg/day; maximum 500 mg/day)
Study: 23571365
Drug: Enhanced daily
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced daily cleaning of ICU room surfaces
Study: 21983354
Drug: Epaxal(®) 0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epaxal(®) 0.25 mL
Study: 21983354
Drug: Epaxal(®) 0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epaxal(®) 0.5 mL
Study: 19233181
Drug: Celecoxib (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib (both doses)
Study: 16309928
Drug: MSM 3g
Normalized name: MSM
DrugBank: Dimethyl sulfone (DB14090)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MSM 3g twice a day for 12 weeks (6g/day total)
Study: 15639691
Drug: capsule dry
Normalized name: Dry Powder Inhaler
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule dry powder inhaler (cDPI)
Study: 9421103
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tamoxifen (TAM) 480 mg daily (Group-1)
Study: 8273245
Drug: Steroid lotion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid lotion with additives
Study: 8273245
Drug: Plain steroid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plain steroid lotion
Study: 31253613
Drug: Digital medicine
Normalized name: Medicaine Sting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Digital medicine system (DMS) comprising an oral sensor tablet coencapsulated with an antipsychotic (aripiprazole, olanzapine, quetiapine, or risperidone), non-medicated wearable patch, mobile application, and web-based dashboard.
Study: 28087928
Drug: 3 months
Normalized name: TABLET, DOSE PACK, 3 MONTHS
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 months of weekly directly observed therapy
Study: 28087928
Drug: 9 months
Normalized name: treprostinil
DrugBank: Treprostinil (DB00374)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 9 months of daily self-administered therapy
Study: 24968251
Drug: Testosterone replacement
Normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Testosterone replacement therapy (TRT) with 5 or 10 mg transdermal T patch daily for 12 months
Study: 19635169
Drug: Oral heme
Normalized name: Heme arginate
DrugBank: Heme arginate (DB17310)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral heme iron polypeptide (HIP; Proferrin ES) - 1 tablet twice daily
Study: 19635169
Drug: Slow-release ferrous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow-release ferrous sulphate - 1 tablet twice daily (control)
Study: 16684267
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg of methanolic extract of L. pacari (n = 55)
Study: 15087552
Drug: Intensive exercise
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive exercise therapy with immobilization of the unimpaired arm (forced use)
Study: 15087552
Drug: Intensive exercise
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive exercise therapy without immobilization of the unimpaired arm (forced use)
Study: 9235493
Drug: 2.4 million
Normalized name: penicillin G benzathine 2.4 million unit INTRAMUSC VIAL (EA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 million units of penicillin G benzathine
Study: 9235493
Drug: Enhanced therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced therapy with 2.4 million units of penicillin G benzathine plus a 10-day course of amoxicillin and probenecid
Study: 24731365
Drug: Soybean oligosaccharides
Normalized name: SOYBEAN
DrugBank: Soybean (DB10568)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soybean oligosaccharides (SBOS) combined with insulin treatment
Study: 23250527
Drug: Imudon therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imudon therapy in combination with traditional methods
Study: 20461807
Drug: Perampanel 0.5
Normalized name: perampanel 0.5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perampanel 0.5 mg
Study: 20461807
Drug: Perampanel 1
Normalized name: perampanel 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perampanel 1 mg
Study: 14505813
Drug: 14 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 g/day fish oil (HFO)
Study: 14505813
Drug: 7 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 g/day of both safflower oil and fish oil (LFO)
Study: 14505813
Drug: 14 g/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 g/day safflower oil (SO)
Study: 8805993
Drug: Clodronate (1600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clodronate (1600 mg/day, orally)
Study: 8805993
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no clodronate treatment)
Study: 6397863
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium (1100 mg daily)
Study: 6397863
Drug: Mefenamic acid
Normalized name: Mefenamic Acid
DrugBank: Mefenamic acid (DB00784)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Mefenamic acid (1500 mg daily)
Study: 27329438
Drug: 1 g
Normalized name: Molds 1 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 g of intravenous tranexamic acid (TXA)
Study: 23564447
Drug: Myocardial contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myocardial contrast echocardiography (MCE) and low-dose dobutamine stress echocardiography (LD-DSE) in Group B (n=27)
Study: 23564447
Drug: Myocardial contrast
Normalized name: Contrased
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myocardial contrast echocardiography (MCE) and low-dose dobutamine stress echocardiography (LD-DSE) in Group A (n=26)
Study: 22440854
Drug: High polyphenol
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High polyphenol content olive oil (HPC: 366 mg/kg)
Study: 22440854
Drug: Low polyphenol
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low polyphenol content olive oil (LPC: 2.7 mg/kg)
Study: 17294383
Drug: Fixed combination
Normalized name: Progestogens and estrogens, fixed combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed combination of bimatoprost 0.03%/timolol 0.5%
Study: 17294383
Drug: Non-fixed combination
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-fixed combination treatment
Study: 12714816
Drug: PCT as
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCT as a prognostic indicator for valve replacement and response to medical treatment.
Study: 12714816
Drug: PCT levels
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCT levels to guide antimicrobial therapy before culture results.
Study: 10588312
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg orally once daily for 5 days
Study: 10588312
Drug: Clarithromycin 500
Normalized name: clarithromycin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clarithromycin 500 mg orally twice daily for 7 days
Study: 8629205
Drug: Endoscopic thermal
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endoscopic thermal therapy (multipolar electrocautery or heater probe) and injection therapy
Study: 1991216
Drug: 2 ml
Normalized name: ethanol 2 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 ml 1% lignocaine
Study: 6340813
Drug: Natural prostaglandin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Natural prostaglandin E2 tablets
Study: 6340813
Drug: Synthetic prostaglandin
Normalized name: Synthetic camphor
DrugBank: Synthetic camphor (DB14156)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Synthetic prostaglandin E2 tablets
Study: 28624695
Drug: S49076 (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: S49076 (600 mg qd)
Study: 28624695
Drug: S49076 (various
Approvals — FDA: no, EMA: no, PMDA: no
Description: S49076 (various doses from 15 to 900 mg)
Study: 23963731
Drug: Ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ferric carboxymaltose (FCM) 750 mg administered in one week
Study: 23963731
Drug: Iron sucrose
Normalized name: Iron Sucrose
DrugBank: Iron sucrose (DB09146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iron sucrose 200 mg administered in up to five infusions in 14 days
Study: 15124080
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of Isatis tinctoria extracts during the ICD eliciting phase
Study: 15124080
Drug: Topical application
Normalized name: Talc Topical application Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical application of tryptanthrin during the ICD eliciting phase
Study: 15124080
Drug: Treatment after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment after the eliciting phase